collection
MENU ▼
Read by QxMD icon Read
search

MS

shared collection
4 papers 0 to 25 followers
https://www.readbyqxmd.com/read/25344587/the-use-of-multiple-population-based-data-sources-for-estimating-ms-sex-ratio-trends-over-time
#1
EDITORIAL
Maria Trojano
No abstract text is available yet for this article.
October 2014: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/25344375/effect-of-alfacalcidol-on-multiple-sclerosis-related-fatigue-a-randomized-double-blind-placebo-controlled-study
#2
RANDOMIZED CONTROLLED TRIAL
Anat Achiron, Uri Givon, David Magalashvili, Mark Dolev, Sigal Liraz Zaltzman, Alon Kalron, Yael Stern, Zeev Mazor, David Ladkani, Yoram Barak
CONTEXT: Fatigue is one of the most common and disabling symptoms of multiple sclerosis (MS); however, there is no medication that has been approved specifically to treat MS-related fatigue. OBJECTIVE: We aimed to evaluate the effect of vitamin D analogue, Alfacalcidol, on MS-related fatigue. DESIGN, SETTINGS, PARTICIPANTS: This was a randomized, double-blind, parallel group, placebo-controlled trial in patients with clinically definite MS by McDonald criteria conducted in a single university-affiliated medical center in Israel...
May 2015: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/25344374/alemtuzumab-a-new-therapy-for-active-relapsing-remitting-multiple-sclerosis
#3
REVIEW
Hans-Peter Hartung, Orhan Aktas, Alexey N Boyko
Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for the treatment of active relapsing-remitting MS. Alemtuzumab, administered intravenously, was shown to improve relapse rate versus subcutaneous interferon beta-1a in patients who were treatment-naive (CAMMS223 and CARE-MS I) or had relapsed on prior therapy (CARE-MS II), and to reduce sustained accumulation of disability (CAMMS223 and CARE-MS II)...
January 2015: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/25344373/antibodies-to-mog-and-aqp4-in-adults-with-neuromyelitis-optica-and-suspected-limited-forms-of-the-disease
#4
Romana Höftberger, María Sepulveda, Thaís Armangue, Yolanda Blanco, Kevin Rostásy, Alvaro Cobo Calvo, Javier Olascoaga, Lluís Ramió-Torrentà, Markus Reindl, Julián Benito-León, Bonaventura Casanova, Georgina Arrambide, Lidia Sabater, Francesc Graus, Josep Dalmau, Albert Saiz
OBJECTIVE: We aimed to report the frequency and implications of antibodies to myelin oligodendrocyte glycoprotein (MOG-ab) in adults with demyelinating syndromes suspicious for neuromyelitis optica (NMO). METHODS: Samples from 174 patients (48 NMO, 84 longitudinally extensive myelitis (LETM), 39 optic neuritis (ON), and three acute disseminated encephalomyelitis (ADEM) who presented initially with isolated LETM) were retrospectively examined for AQP4-ab and MOG-ab using cell-based assays...
June 2015: Multiple Sclerosis: Clinical and Laboratory Research
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"